bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 5866: Racial ethnic variations in trajectory of health-related quality of life in older women with breast cancer
Authors: Rupesh Sushantti , Lee Eunkyung 
Published: June 2022

Abstract
The purpose of the research study was to explore the ethnic/racial variations in health-related quality of life (HRQoL) scores, and the trajectory of comorbidities in older women with breast cancer. This study analyzed data from the Surveillance, Epidemiology, and End-Results (SEER) – Medicare Health Outcomes Survey (MHOS) linked data resource. The study population consists of 982 women (≥ 65 years old at diagnosis) with primary breast cancer who were diagnosed in 1998-2012 and completed the MHOS survey within 24 months before diagnosis and completed at least one more survey after diagnosis. The study population was grouped into three ethnic/racial groups: Whites (n=791), Black/African American (n=104) and Hispanics (n=87). The mean age of the population was 74.8 ± 6.1. HRQoL was measured using SF-36/VR-12 questionnaire and summarized as Physical Component Summary (PCS) Score and a Mental Component Summary (MCS) Score. Results showed an increase in the PCS score at month 6 after diagnosis, and a decrease at month 12 was observed in Whites and Black/African Americans. A continuous decrease in the PCS score till month 12 and an increase at month 24 was observed in Hispanics. All three groups showed similar trends in MCS scores over time - the MCS score dropped at month 6 but was back at baseline by month 12. The Whites had the highest MCS score out of the three, and Hispanics had the lowest. The MCS score for Hispanics decreased by month 36, whereas it increased for Black/African Americans. The MCS score for Whites remained fairly the same. The results also showed an increase in the total number of comorbidities at month six after diagnosis, along with a decrease to the baseline comorbidities by month 12. Hispanics had the highest increase in comorbidities at month 6 and Whites had the lowest and most stable. The number of comorbidities remained fairly the same in Whites and Black/African Americans, whereas the number of comorbidities increased slightly at month 24 for Hispanics and drastically increased at month 36. Overall, changes in the total number of comorbidities had a negative correlation with the changes in MCS scores, therefore it can be concluded that the number of comorbidities have a negative effect on a patient’s mental health. Whites were observed to have less comorbidities and better MCS scores than Black/African Americans or Hispanics. The information gained from this study will help clinicians and patients in the shared treatment decision process and guide individualized survivorship care plans among older women with breast cancer.
Citation Format: Sushantti Rupesh, Eunkyung Lee. Racial ethnic variations in trajectory of health-related quality of life in older women with breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5866.
Abstract 5888: Trends in incidence of gallbladder cancer in all 50 United States from 2001 to 2018
Authors: Raza Syed A. , Costa Wilson L. , Thrift Aaron P. 
Published: June 2022

Abstract
Background: Gallbladder cancer (GBC) is an aggressive malignancy of the gastrointestinal system that is historically more common among racial/ethnic minority populations in the US. We investigated trends in GBC incidence rates in all 50 states from 2001 to 2018, overall and stratified by race/ethnicity, sex, and different regions.
Methods: Age-standardized incidence rates and trends in adults aged ≥35 years were calculated using data from the U.S. Cancer Statistics registry. We used joinpoint regression to compute annual percent changes (APC) and average annual percent changes (AAPC) and corresponding 95% confidence intervals (CI) for both sexes and used eleven 5-year age groups (35-39 years through 85+ years). Race/ethnic groups were classified as non-Hispanic Whites and Blacks (NHWs and NHBs), Hispanics, American Indians/Alaska Natives, and Asians and Pacific Islanders.
Results: Overall, the age-standardized incidence rate for GBC decreased by 0.3% annually between 2001 and 2018 (95% CI -0.5%, -0.1%). However, secular trends varied by age-group, sex and race/ethnicity. APC increased among individuals aged 45-54 years from 1.2% to 1.4% but decreased among those who were ≥ 75 years (-0.7% to -1.6% per year). While GBC incidence rates were stable among men between 2001 and 2014, incidence rates decreased by over 2% per year between 2014 and 2018 (APC, -2.1%; 95%CI: -3.9, -0.3). GBC incidence remained relatively stable between 2001 and 2018 among women. While GBC rates declined in other racial/ethnic groups, the rates increased by 1.4% annually among non-Hispanic Blacks (NHBs) between 2001 and 2018 (APC=1.4%; 95%CI: 0.9%, 2.0%). Among NHBs, increasing trends were also noted in Northeast, Midwest, and South regions of US.
Conclusions: The study shows increasing incidence trends for GBC in the US among NHBs from 2001-2018 compared to decreasing trends among other race/ethnic groups. The results also point to the need for studying equitable detection and treatment of underlying risk factors for GBC.
Citation Format: Syed A. Raza, Wilson L. Costa, Aaron P. Thrift. Trends in incidence of gallbladder cancer in all 50 United States from 2001 to 2018 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5888.
Abstract 5928: MTA1-targeted interception by natural stilbenes in high-risk prostate cancer
Authors: Levenson Anait S. 
Published: June 2022

Abstract
Active surveillance subpopulation of patients with prostate cancer includes men with varying cancer risk categories of precancerous disease due to prostatic intraepithelial neoplasia (PIN) heterogeneity. Identifying molecular alterations associated with PIN can provide preventable measures through finding novel targets for cancer interception, specifically by active dietary polyphenols with potent biological properties including anti-inflammatory, anti-oxidant, and anticancer effects. A large volume of preclinical evidence shows that natural stilbenes produce anticancer responses in a variety of cell lines and animal models of different types of cancer, including solid tumors as well as hematological malignancies. However, identification of a particular target with clinical relevance is rare. I will discuss the potent MTA1-targeted anticancer effects of natural stilbenes (resveratrol, pterostilbene, and Gnetin C) observed in unique preclinical models of prostate cancer mimicking high-risk premalignant tumors with overexpressed MTA1. We have shown that MTA1 cooperates with PTEN deficiency to accelerate high-grade PIN development through MTA1-associated signaling. We further demonstrated that stilbene supplemented diets lead to more favorable histopathology with decreased severity and number of PIN foci accompanied with reduced proliferation, inflammation, and angiogenesis concomitant to reduction of MTA1-associated signaling, including specific miRNAs. Together, our preclinical data provide strong evidence for the potential of stilbenes as promising natural agents for MTA1-targeted interceptive strategy. Human cancer prevention trials for protecting select patients with high MTA1 from developing into full-fledged disease are urgently needed. This can be one extra forward step towards viable and successful interception/chemoprevention potential for prostate cancer with an implication for precision medicine. Supported by NCI/NIH R15CA216070 to ASL.
Citation Format: Anait S. Levenson. MTA1-targeted interception by natural stilbenes in high-risk prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5928.
Abstract 5941: A simulation modeling study to support personalized breast cancer prevention and early detection in high-risk women
Authors: Jayasekera Jinani , Zhao Amy 
Published: June 2022

Abstract
Purpose: To evaluate the impact of early detection with screening and primary prevention with risk-reducing medication to provide personalized data that will help identify women who are more likely to benefit from various interventions or combinations of interventions with the least harms.
Methods: We adapted the CISNET microsimulation model G-E of breast cancer natural history to evaluate the harms and benefits of annual mammography and risk reducing medication among high-risk women (i.e., 5-year risk greater than or equal to 3%). Model G-E is a discrete event microsimulation model that follows millions of women from birth to death and captures the variability in distributions of each event. Each simulated woman is assigned a cohort-specific life expectancy which is used to select a date of breast cancer death. For this study, we dynamically updated the risk of developing breast cancer for each simulated woman based on her family history, breast density, age and history of biopsy. We used large observational and clinical trial data to derive input parameters for cohort-specific birth rates, incidence and stage without screening, other cause mortality by age, screening performance (sensitivity/specificity), survival by age, stage, and subtype without treatment, treatment efficacy, and other cause mortality. We compared model outcomes for screening alone vs. screening with a 5-year course of risk reducing medication. We modeled various screening strategies including annual or biennial screening starting at ages 35, 40, 45 and stopping at ages 65 and 74 years. Model outcomes for each strategy included, the benefits of risk-reducing drugs (avoiding breast cancer) and screening (breast cancer stage, breast cancer-specific survival), and harms of screening (false positives, overdiagnosis). We also conducted sensitivity analysis to estimate the effects of uncertainty in model inputs or assumptions on results.
Results: We found that risk reducing medication could result in an additional 28% decrease in invasive breast cancer incidence, 20% decrease in stage IV diagnosis, and a 30% decrease in breast cancer death if screening started at age 35 in a high-risk woman. However, potential breast density changes due to risk reducing medication among high-risk women could result in a 19% increase in false positive screening results compared to screening alone. The results varied by the starting age of screening.
Conclusions: Simulation modeling is useful in assessing the relative benefits and harms of screening and risk reducing medication in high-risk women.
Citation Format: Jinani Jayasekera, Amy Zhao. A simulation modeling study to support personalized breast cancer prevention and early detection in high-risk women [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5941.
Abstract 5945: Gnetin C for chemoprevention and chemotherapy of prostate cancer
Authors: Campanelli Gisella , Al Deabel Rabab , Puaar Anand , Parupathi Prashanth , Adhvaryu Amee , Kumar Avinash , Levenson Anait S. 
Published: June 2022

Abstract
Prostate cancer is common among aging men. No cancer treatment is provided during active surveillance for prostate cancer. Targeted nutritional interception may prove to be the most appropriate chemoprevention for intermediate- and high-risk patients. Here, for the first time, we investigate the efficacy of Gnetin C, a resveratrol-dimer found abundantly in melinjo (Gnetum gnemon) plant that is characterized with improved pharmacokinetics compared to other stilbenes, in a transgenic mouse model of prostate cancer. We have generated two prostate-specific mouse models, one overexpressing MTA1 on the background of Pten heterozygosity (R26MTA1; Pten+/f), and the other overexpressing MTA1 on the background of Pten loss (R26MTA1; Ptenf/f). Chemoprevention design included Gnetin C- dietary supplementation in the high-risk model while the therapeutic design included i.p. administration in the more aggressive R26MTA1; Ptenf/f genotype. Our results show that while MTA1 cooperates with PTEN deficiency to accelerate PIN development by increasing MTA1-associated signaling, Gnetin C intervention combats the progression of prostate cancer. We show that mice treated with Gnetin C (7 mg/kg bw, daily i.p.) exhibited more favorable histopathology with decreased severity and number of PIN foci (41.23% reduction) accompanied by reduced proliferation (Ki67, 57.43% reduction), angiogenesis (CD31, 86.91% reduction), AR (31.57% reduction), and MTA1 (27.94% reduction). Ongoing chemopreventive studies with four different diets [Control-diet; Gnetin C high dose (70 mg/kg diet); Gnetin C low dose (35 mg/kg diet); and pterostilbene (70 mg/kg diet)] are in progress. Altogether, these data provide an evidence for efficacy of Gnetin C in blocking prostate cancer progression and reveal its potential for novel chemopreventive and therapeutic implications in prostate cancer.Supported by NCI/NIH R15CA216070 to ASL
Citation Format: Gisella Campanelli, Rabab Al Deabel, Anand Puaar, Prashanth Parupathi, Amee Adhvaryu, Avinash Kumar, Anait S. Levenson. Gnetin C for chemoprevention and chemotherapy of prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5945.
Abstract 5965: The effectiveness of health care professional training on the legal issues impacting individuals diagnosed with cancer to improve patient quality of life
Authors: Ward Madison McMahon , Morales Joanna Fawzy , Bryant Monica Fawzy 
Published: June 2022

Abstract
A cancer diagnosis may carry with it a variety of legal issues, including navigating insurance, government benefits, employment, and consumer rights. These legal issues can cause people unnecessary worry, confusion, and stress, and can be overwhelming. The Insurance and Finance Intensive provides health care professionals tools to proactively identify the presence of cancer-related legal, insurance, and financial issues facing their patients. Additionally, the training helps health care professionals to offer referrals to appropriate legal and related resources, once those issues are identified. Oncology health care professionals participated in an eight-hour comprehensive training. Attendees were provided with substantive information about cancer-related legal issues, such as identifying health insurance options, navigating taking time off work and accessing disability insurance, and managing finances. A follow-up survey was sent to past 2020 and 2021 Intensive attendees (n=126), to measure the effectiveness of the training and to address additional questions and difficult case studies. Ninety-four percent of survey respondents indicated that they changed their behavior or practice based on what they learned at the training. Ninety-four percent of survey respondents strongly agreed or agreed that the information provided by the training helped reduce the financial burden that their patients and families experience after a cancer diagnosis. Ninety-seven percent of respondents strongly agreed or agreed that the information provided by the training improved the quality of life of their patients and families. The Insurance & Finance Intensive successfully provided health care professionals with valuable information on the practical and legal issues that impact individuals diagnosed with cancer. It is recommended that more health care professionals participate in this training to mitigate the financial burden of a diagnosis and improve the quality of life of their patients.
Citation Format: Madison McMahon Ward, Joanna Fawzy Morales, Monica Fawzy Bryant. The effectiveness of health care professional training on the legal issues impacting individuals diagnosed with cancer to improve patient quality of life [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5965.
Abstract 5966: Melanoma revisited; The need for bio-banking and precision oncology, a study from a resource limited setting
Authors: Adoke Kasimu Umar , Haruna Sanusi Mohammed 
Published: June 2022

Abstract
Since the incidence of Malignant melanoma (MM) is rising, we propose high quality patient samples bio-bank for proper understanding of the disease and with time analyze on a large scale proteogenomics. There is increased need to support research and help improved patient care and outcome. Bio-banking in MM will provide high quality and well define tissue and bio-fluid specimens.
Materials and Methods: Large scale sample collection were done for 22 patients with histological diagnosis of MM. The patients consent and hospital ethical approval was sorted for the study, with patients' fresh frozen tissue and blood samples collected, fractionated and stored in an automated bio-bank. Five patients however did not consent for bio-banking of their samples.
Results: Patients that consented to sample collection had proteogenomic studies and other studies were done on their specimens with possibilities of new treatments for the patients and precision oncology for these patients tailored on their unique genomic landscape.
Conclusion: Bio -banking on a large scale is possible and helpful in MM patient especially in our environment where most patients are lost to follow up and have high degree of resistance and mortality during chemo radiation treatment.
Citation Format: Kasimu Umar Adoke, Sanusi Mohammed Haruna. Melanoma revisited; The need for bio-banking and precision oncology, a study from a resource limited setting [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5966.
Abstract 598: A novel allosteric CBL-B inhibitor with differentiated immune enhancing activity in preclinical models
Authors: Qi Yilin , Kuai Jun , Bi Yingzhi , Sun Huadong , Conrady Deborah G. , Govindaraj Rajiv G. , Hone Graham , Denny Rajiah A. , Carson Ken , Reilly Timothy , Harriman Geraldine , Wang Fang 
Published: June 2022

Abstract
E3 ligase Casitas B-Lineage Lymphoma Proto-Oncogene B (CBL-B) is a key negative modulator of T-cell receptor and co-stimulatory regulation. CBL-B inhibition lowers the threshold of antigen-specific T cell activation, even in absence of co-stimulatory signaling or the presence of an immune suppressive environment. Genetic ablation of Cbl-b or functional inactivation of its E3 ligase activity in mice or primary human T cells enhances immune-mediated tumor growth control. Therefore, CBL-B inhibition may address the suboptimal response to current immunotherapies due to low inflammation, no/low co-stimulation signal or a high immune suppressive environment. We have identified a series of potent allosteric CBL-B inhibitors via the application of our proprietary Smart Allostery࣪ platform. Herein we demonstrate one of our lead CBL-B inhibitors showed superior activity compared to a competitor CBL-B inhibitor (NX-519) in both biochemical and cellular assays. At similar exposures in a syngeneic mouse tumor model (CT26), our CBL-B inhibitor also demonstrated an increase in tumor growth inhibition relative to NX-519. Mechanistically, our CBL-B inhibitor not only enhanced T cell activation, but also re-invigorated exhaustive T cells and caused resistance to T regulatory cell-mediated suppression, both in a concentration-dependent manner. We further demonstrated differentiation of CBL-B inhibition versus anti-PD1 and anti-CTLA4 in the mixed lymphocyte reaction (MLR) assay. Our CBL-B inhibitor significantly promoted T cell proliferation where anti-PD1 alone and anti-CTLA4 alone did not. Both anti-PD1 and CBL-B inhibition increased IFNγ production in this MLR assay, but that effect was further enhanced in combination. Together, the pre-clinical data presented here provided evidence of a differentiated profile of our allosteric CBL-B inhibitors to enhance key parameters associated with T cell activation and reduce susceptibility to immune suppression, supporting their further progression toward clinical development.
Citation Format: Yilin Qi, Jun Kuai, Yingzhi Bi, Huadong Sun, Deborah G. Conrady, Rajiv G. Govindaraj, Graham Hone, Rajiah A. Denny, Ken Carson, Timothy Reilly, Geraldine Harriman, Fang Wang. A novel allosteric CBL-B inhibitor with differentiated immune enhancing activity in preclinical models [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 598.
Abstract 5982: Single-cell RNA sequencing (scRNA-Seq) from mice model reveals metastatic and stemness signatures in esophageal squamous cell carcinoma (ESCC)
Authors: Wong Ching Ngar , Zhang Yu , Ru Beibei , Zhou Hong Yu , Lam Kwong Yiu , Guan Xin Yuan 
Published: June 2022

Abstract
Remote oligometastases are the predominant roots of the unsatisfactory 5-year survival rate in esophageal squamous cell carcinoma (ESCC) patients. The title of metastatic-initiating cells (MICs) has been designated to describe tumor subpopulation with heterogeneous genetic background and behaviors that potentially displays stemness features and favors metastatic lesion formation. However, preceding studies have overpassed the early surviving MICs due to limitations in bulk transcriptomic sequencing at macrometastatic stage. With the aim of denoting and characterizing MICs in ESCC, we established the pulmonary metastatic mice model via intravenous injection and followed by multiplex single-cell RNA sequencing (scRNA-Seq) of tumor cells collected from lung tissues along longitudinal end-points. The scRNA-Seq results uncover a 7-gene surface marker signature panel that could depict the early surviving MICs of ESCC, including CD44, TACSTD2, TM4SF1, S100A14, RHOD, CST6, and C19orf33. In silico gene ontology (GO) enrichment of the early surviving MICs subpopulation reveals numerous migration and adhesion-related biological processes (p&lt;0.05). In addition to scRNA-Seq, immunohistochemistry (IHC) staining of tumor cells in mice lungs collected in sequential order evidenced the survival heterogeneity of tumor subpopulations. Likewise, flow cytometry fluorescence-activated cell sorting (FACS) of signature-enriched tumor cells was performed to resemble the target MICs. CD44Pos ESCC cells are found to show distinctively greater wound-healing (p&lt;0.01), foci formation (p&lt;0.05), migration (p&lt;0.01) and invasion (p&lt;0.01) ability than CD44Neg cells in vitro, and longer survival patterns (p&lt;0.05) upon implantation in vivo. Multi-color immunofluorescence (mIF) staining of these gene signatures is underway in mice models and clinical samples for comprehensive validation. We anticipate this surface marker signature to accelerate development for clinical diagnosis together with molecular targeting in metastatic ESCC patients.
Citation Format: Ching Ngar Wong, Yu Zhang, Beibei Ru, Hong Yu Zhou, Kwong Yiu Lam, Xin Yuan Guan. Single-cell RNA sequencing (scRNA-Seq) from mice model reveals metastatic and stemness signatures in esophageal squamous cell carcinoma (ESCC) [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5982.